Doctor of Osteopathy Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Teresa Hubka

Obstetrics & Gynecology Chicago, IL Doctor of Osteopathy

NPI 1659354140 CMS profile 74315

3152 N Lincoln Ave, Chicago, IL 60657

Open in the dashboard

General payments

$62,104

103 records reported · program years 2020–2025

Research payments

$6,652

Paid to them · 3 records reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Teresa Hubka of Chicago, IL is reported in the CMS Open Payments database as having received $62,104 across 103 general payments and $6,652 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,005 9
2024 General $8,047 17
2023 General $37,504 39
2022 General $7,385 19
2021 General $2,032 12
2020 General $130 7
2020 Research $6,652 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Teresa Hubka
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Teresa Hubka were reported at $7,005. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Teresa Hubka Obstetrics & Gynecology median Middle half National median
2019 $0 $172 $62–$391 $163
2020 $130 $94 $36–$222 $114
2021 $2,032 $136 $42–$369 $132
2022 $7,385 $160 $50–$433 $149
2023 $37,504 $169 $56–$423 $160
2024 $8,047 $152 $50–$371 $164
2025 $7,005 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Astellas Pharma US Inc $50,384 44 payments
  2. Astellas Pharma Global Development $8,822 3 payments
  3. AbbVie, Inc. $2,057 12 payments
  4. CooperSurgical, Inc. $360 25 payments
  5. Shield Therapeutics Inc $75 1 payment
  6. Hologic Inc $72 1 payment
  7. Sumitomo Pharma America, Inc. $56 2 payments
  8. Hologic, LLC $55 3 payments
  9. Exact Sciences Corporation $51 2 payments
  10. Mayne Pharma Inc. $51 3 payments
  11. Other $123 7 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $43,254 18 payments
  2. Consulting Fee $10,643 3 payments
  3. Travel and Lodging $6,206 12 payments
  4. Food and Beverage $2,002 70 payments
Products named General payments · program years 2020–2025
  1. Veozah $46,625 37 payments
  2. ORILISSA $1,938 6 payments
  3. Paragard $197 14 payments
  4. PARAGARD T 380A $163 11 payments
  5. LO LOESTRIN FE $120 6 payments
  6. ORIAHNN $113 5 payments
  7. ACCRUFER $75 1 payment
  8. CoolSeal Generator $72 1 payment
  9. FLUENT FLUID MANAGEMENT SYSTEM $72 1 payment
  10. MYOSURE TISSUE REMOVAL DEVICE $72 1 payment
  11. Other $393 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2020–2025
  1. AbbVie, Inc. $6,652 3 payments

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$2,363

Medicare's payments for the services billed

Medicare patients

11

Average age 70

Services billed

25

11 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Heart failure 0%
Atrial fibrillation 0%
COPD 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $7,266
$7,266 — —
MYFEMBREE
  • Sumitomo Pharma America, Inc. $28
$28 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

106 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record